Baird Financial Group’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Baird Financial Group’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-33,338	Closed	-$963K	–	1768
2022 Q2	$963K	Sell	33,338 -8,041	-19%	-$240K	﹤0.01%	1095
2022 Q1	$1.43M	Sell	41,379 -8,849	-18%	-$313K	﹤0.01%	1009
2021 Q4	$2.2M	Buy	50,228 +1,355	+3%	+$64.1K	0.01%	898
2021 Q3	$2.48M	Buy	48,873 +1,772	+4%	+$92.4K	0.01%	863
2021 Q2	$2.45M	Buy	47,101 +3,147	+7%	+$148K	0.01%	830
2021 Q1	$2.01M	Buy	+43,954	New	+$2.15M	0.01%	881

Other funds holding IDNA

WBG

Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

WAP

Wealthcare Advisory Partners West Chester, Pennsylvania $5.27B AUM 22.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Baird Financial Group's IDNA Position: Q3 2022 in Review

Baird Financial Group sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q3 2022, closing a stake of 33,338 shares — an estimated $963K sold.

Baird Financial Group first reported a position in IDNA in Q1 2021 and held it in 6 quarters. The position peaked at $2.48M in Q3 2021. 67 funds tracked by Wall St. Rank hold IDNA as of Q3 2022.

Baird Financial Group reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q3 2022 after selling out during the quarter.
Baird Financial Group sold 33,338 iShares Genomics Immunology and Healthcare ETF shares in Q3 2022, an estimated $963K.
Baird Financial Group first reported a position in iShares Genomics Immunology and Healthcare ETF in Q1 2021 and held it in 6 quarters.
Baird Financial Group's iShares Genomics Immunology and Healthcare ETF position peaked at $2.48M in Q3 2021.
67 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q3 2022.

Based on Baird Financial Group's 13F filing for Q3 2022, filed 15 Nov 2022.